Selection of a panel of biomarkers of central pain processing and modulation, and assessment of their validity to predict chronic pain in patients with cancer - WP1

IPO Porto0 sites450 target enrollmentJuly 21, 2023

ConditionsCancer

Overview

2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38849731/ (added 10/06/2024)

Registry

who.int

Start Date

July 21, 2023

End Date

October 1, 2025

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

IPO Porto

•1\. Adult subjects \=18 years old
•2\. Able to provide informed consent to participate in the study
•3\. Able to self\-report pain
•4\. Recent diagnosis (less than 6 months) of cancer affecting the lung, breast, pancreas or colon (with metastases or not)
•5\. Not having started cancer treatment (all treatments are included)
•6\. Have a life expectancy of at least 12 months
•7\. Ability to use the internet and WhatsApp or have a person (family member, caregiver) to help them

•1\. Pregnant women or women of fertile age not having efficacious contraception during the whole period of the study
•2\. Neurological and psychiatric disease (except anxiety and depression)
•3\. Unstable medical conditions (e.g., uncontrolled diabetes, uncompensated cardiac issues, heart failure or chronic obstructive pulmonary disease)
•4\. History of neurosurgery, traumatic brain injury with loss of consciousness, and/or cortical lesions
•5\. History of non\-malignant chronic pain